Research Article
Circulating Semaphorin 4D as a Marker for Predicting Radiographic Progression in Patients with Rheumatoid Arthritis
Table 3
Comparisons of clinical and laboratory data between RA patients with and without radiographic progression.
| | Characteristics | Progressor () | Nonprogressor () | value |
| | Age (years) | 56 [45–66.3] | 51 [43–60] | 0.036 | | Age > 60-year-old | 22 (44.0) | 19 (23.8) | 0.016 | | Female | 41 (82.0) | 70 (87.5) | 0.388 | | Body mass index (kg/m2) | 23.2 [20.2–24.9] | 22.0 [20.1–24.6] | 0.578 | | Disease duration (months) | 43.3 [5.0–115.1] | 12.5 [2.2–75.2] | 0.250 | | Current smoker | 7 (17.9) | 9 (12.3) | 0.418 | | ESR (mm/hr) | 22.5 [10–40.3] | 18.5 [10–36.5] | 0.535 | | CRP (mg/dL) | 0.71 [0.14–2.03] | 0.65 [0.13–1.45] | 0.555 | | 66 swollen joint count | 4 [0.5–7.5] | 4 [1–9] | 0.928 | | 68 tender joint count | 3 [0–5] | 4 [0–9] | 0.485 | | DAS28-ESR | 3.22 [4.08–5.19] | 4.06 [2.60–5.06] | 0.456 | | Active RA (DAS28-ESR > 3.2) | 36 (73.5) | 46 (60.5) | 0.137 | | RF positivity | 38 (76.0) | 64 (81.0) | 0.495 | | Anti-CCP positivity | 41 (85.4) | 71 (91.0) | 0.331 | | DMARDs-naïve | 34 (68.0) | 43 (53.8) | 0.108 | | Current RA medications | | Glucocorticoid | 27 (54.0) | 31 (38.8) | 0.089 | | Methotrexate | 22 (44.0) | 36 (45.0) | 0.911 | | Hydroxychloroquine | 16 (32.0) | 13 (16.3) | 0.036 | | Sulfasalazine | 4 (8.0) | 6 (7.5) | 0.583 | | Leflunomide | 8 (16.0) | 13 (16.3) | 0.970 | | Cyclosporin A | 3 (6.0) | 1(1.3) | 0.158 | | Tacrolimus | 8 (16.0) | 3 (3.8) | 0.018 | | Semaphorin 4D (ng/mL) | 115.6 [66.1–221.7] | 80.4 [54.3–119.7] | 0.029 | | Semaphorin 3A (ng/mL) | 0.73 [0.16–2.29] | 0.25 [0–1.65] | 0.083 | | Dkk-1 (ng/mL) | 4.706 [3.971–5.410] | 4.591 [3.777–5.416] | 0.787 | | IL-22 (pg/mL) | 0 [0–0] | 0 [0–0] | 0.073 | | IL-23 (pg/mL) | 0 [0–8.7] | 0 [0–8.7] | 0.393 | | IL-6 (pg/mL) | 12.9 [3.3–50.4] | 6.6 [2.9–18.2] | 0.156 | | Osteopontin (pg/mL) | 6.63 [2.90–13.33] | 5.38 [2.00–12.10] | 0.271 | | Sclerostin (pg/mL) | 25.3 [12.6–46.7] | 26.9 [12.6–53.4] | 0.945 | | TNF-α (pg/mL) | 1.89 [0.37–4.09] | 2.75 [0.84–3.91] | 0.451 | | Baseline modified SHS | 8 [1–23.3] | 1 [0–11.5] | 0.003 | | Erosion | 3 [0–12] | 1 [0–5.8] | 0.019 | | Joint space narrowing | 6 [3–16.8] | 0 [0–5] | 0.002 |
|
|
Values are expressed as the median [IQR 25–75%] or (%) unless stated otherwise. ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: disease activity score 28; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide; DMARDs: disease-modifying antirheumatic drugs; Dkk-1: Dickkopf-1; IL: interleukin; TNF- α: tumor necrosis factor- α; SHS: Sharp van der Heijde score. |
